Full-Time

Scientist – LNP Discovery

Posted on 7/19/2025

Strand Therapeutics

Strand Therapeutics

51-200 employees

Develops programmable, long-acting mRNA therapeutics

Compensation Overview

$100k - $140k/yr

+ Bonus + Equity Incentives

Boston, MA, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • B.S. or Advanced Degree with 6-7+ years of industry experience with a focus on lipid chemistry, nanoparticle formulation and in vivo delivery of nucleic acid-based payloads
  • Experience with lipid chemistry required
  • Experience with production and analytical characterization of (lipid) nanoparticles required
  • Prior experience with (high throughput) screenings of (lipid) nanoparticles preferred
Responsibilities
  • Help advance Strand’s mRNA delivery platform and capabilities.
  • Lead and contribute to lipid innovation and development/optimization of lipid nanoparticle (LNP) formulations.
  • Characterize the physicochemical properties and evaluate therapeutic indices of (lipid) nanoparticle formulations using standard or newly developed in-house assays.
  • Execute LNP composition optimization and screening assays.
  • Produce (lipid) nanoparticle formulations to support internal and partnered programs.
  • Compile data reports and communicate the results with relevant team(s).
  • Research and identify new opportunities and novel project ideas related to mRNA delivery that support Strand’s vision.
  • Maintain and establish new relationships with outside collaborators which provide access to proprietary (lipid) nanoparticles.
  • Write study protocols, technical reports and SOPs that support the drug discovery efforts of Strand.
  • Interact with IP counsel/consultants to assist with patent prosecution.
Desired Qualifications
  • Prior experience with (high throughput) screenings of (lipid) nanoparticles
  • Prior experience with development of tissue/cell targeting (lipid) nanoparticles would be a plus
  • Excellent knowledge of the scientific literature in the field of mRNA delivery
  • Demonstrated experience working across internal and external research teams
  • Highly analytical, decisive, and goal-oriented while maintaining the highest scientific and ethical standards
  • Ability to quickly adapt to change and thrive in a dynamic and entrepreneurial early-stage environment
  • A strong team player with excellent oral and written communication skills and a demonstrated ability to work independently

Strand Therapeutics develops programmable, long-acting mRNA therapeutics that aim to treat cancer and other life-threatening diseases. The product works by delivering mRNA engineered with logic-based circuits that sense disease-specific cell signals and activate only in diseased cells, increasing the therapeutic window and reducing harm to healthy cells. This enables multi-functional treatments with targeted action rather than non-specific delivery. The company differentiates itself by its programmable mRNA platform that combines gene-encoded logic with disease targeting to achieve cell-type–restricted activity, potentially allowing for safer and more precise therapies compared with conventional mRNA approaches. Strand Therapeutics pursues collaboration and partnerships to expand its programs and generate revenue through development and commercialization of its proprietary mRNA therapeutics with healthcare providers and institutions.

Company Size

51-200

Company Stage

Series B

Total Funding

$256M

Headquarters

Cambridge, Massachusetts

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • STX-001 Phase 1 showed confirmed complete response and partial responses by April 2025.
  • $153M Series B from Regeneron, Lilly, Amgen funds STX-003 Phase 1 in 2026.
  • New CFO Kunal Bhatia and CMO Jason Luke strengthen leadership for Phase 2 transition.

What critics are saying

  • Regeneron's liblocalcin achieves 62% ORR in refractory melanoma, eroding STX-001 edge.
  • FDA clinical hold on self-replicating RNA like Gritstone's halts STX-001 by Q2 2026.
  • Eli Lilly enforces milestone repayment if STX-001 misses 20% ORR in Q4 2026 readout.

What makes Strand Therapeutics unique

  • STX-001 deploys programmable mRNA with logic circuits sensing diseased cells only.
  • Intratumoral STX-001 produces localized IL-12, activating immunity without systemic toxicity.
  • Platform enables cell-type specific, multi-functional mRNA therapies for solid tumors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Life Insurance

Unlimited Paid Time Off

Phone/Internet Stipend

Commuter Benefits

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-4%
The Pharma Data
Aug 23rd, 2025
Strand Therapeutics Names Dr. Jason J. Luke as New Chief Medical Officer

Strand Therapeutics strengthens leadership with appointment of Dr. Jason J. Luke as Chief Medical Officer.

BiopharmaTrend
Aug 11th, 2025
Strand Therapeutics Secures $153 Million for Programmable mRNA Cancer Therapies

Kinnevik's Ala Alenazi, Ph.D., will join Strand's board of directors.

Crunchbase
Aug 8th, 2025
The Week's 10 Biggest Funding Rounds: Public Safety Leads, While Healthcare And Fintech Also See Big Deals

Strand Therapeutics, $153M, biotechnology: Boston-based Strand Therapeutics, a developer of mRNA-based therapeutics, raised $153 million in a Series B funding led by Kinnevik.

Business Wire
Aug 8th, 2025
Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline

Strand Therapeutics raised a $153 million Series B to develop programmable mRNA therapeutics and reshape how we treat disease -- starting with cancer.

BioSpace
Aug 7th, 2025
Big Pharma-Backed mRNA Startup Bags $153M Series B Amid Policy Headwinds

Strand Therapeutics on Thursday closed a $153 million series B round that will help it advance its pipeline of novel mRNA therapies for cancer and other chronic conditions.

INACTIVE